HLB Genex, Inc. (KOSDAQ:187420)
South Korea · Delayed Price · Currency is KRW 2,445.00
+85.00 (3.60%)
At close: Nov 2, 2026
HLB Genex Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 45,670 | 43,370 | 35,430 | 27,008 | 27,802 | 25,874 |
Revenue Growth | 14.42% | 22.41% | 31.18% | -2.85% | 7.45% | 37.85% |
Gross Profit Gross Profit Growth | 16,332 | 15,038 | 14,301 | 7,331 | 10,215 | 9,831 |
Operating Income Operating Income Growth | 1,048 | 1,276 | -1,846 | -9,464 | -6,224 | -3,834 |
Net Income Net Income Growth | 9,264 | 22,591 | -18,828 | -2,950 | -12,968 | -6,817 |
Earnings Per Share EPS Growth | 310.38 | 606.20 | -800.03 | -130.50 | -576.16 | -304.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Enzyme/Material Business Enzyme/Material Business Growth | 45,670 | 43,368 | 35,420 | 25,500 | 27,802 | 25,874 |
New Drug Development New Drug Development Growth | - | 2.09 | 9.35 | 1,508 | - | - |
Total Total Growth | 45,670 | 43,370 | 35,430 | 27,008 | 27,802 | 25,874 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 35,772 | 33,482 | 83,807 | 29,865 | 41,547 | 25,615 |
Total Debt Total Debt Growth | 41,785 | 43,524 | 44,574 | 62,343 | 78,636 | 58,901 |
Net Cash (Debt) Net Cash Growth | -6,014 | -10,043 | 39,233 | -32,477 | -37,089 | -33,286 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -150.47 | -207.26 | 1667.08 | -1436.58 | -1647.83 | -1483.29 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 4,921 | 3,504 | 2,870 | -4,815 | -4,711 | -2,390 |
Capital Expenditures CapEx Growth | -1,379 | -822.46 | -648.89 | -1,212 | -4,021 | -8,712 |
Free Cash Flow Free Cash Flow Growth | 3,543 | 2,682 | 2,221 | -6,028 | -8,732 | -11,102 |
Free Cash Flow Growth | 70.16% | 20.71% | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 35.76% | 34.67% | 40.36% | 27.14% | 36.74% | 38.00% |
Operating Margin | 2.29% | 2.94% | -5.21% | -35.04% | -22.39% | -14.82% |
Pretax Margin | 23.14% | 55.12% | -47.69% | -2.91% | -40.77% | -55.66% |
Profit Margin | 20.28% | 52.09% | -53.14% | -10.92% | -46.64% | -26.35% |
FCF Margin | 7.76% | 6.18% | 6.27% | -22.32% | -31.41% | -42.91% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.88 | 3.42 | - | - | - | - |
Forward PE | - | 83.60 | 83.60 | 83.60 | 83.60 | 83.60 |
P/FCF Ratio | 22.53 | 28.79 | 58.40 | - | - | - |
PS Ratio | 1.75 | 1.78 | 3.66 | 3.29 | 4.42 | 7.10 |